Plain-English answer
U.S. drug pricing flows through manufacturers, PBMs, rebates, formularies, Medicare and commercial plans; Chinese drug pricing increasingly flows through NRDL negotiation, volume-based procurement, reimbursement lists, and payer affordability policy.
How the U.S. side works
U.S. drug access is shaped by list prices, rebates, formularies, pharmacy benefit managers, Medicare Part D, commercial coverage, and patient cost sharing. This produces substantial variation by payer, state, plan design, provider market, coding route, and contracted economics. In practice, a national U.S. answer often fails unless it is narrowed to a payer and setting.
How the China side works
China uses NRDL negotiation, centralized procurement, VBP, hospital listing, and reimbursement rules to pressure prices and expand access selectively. This produces a different kind of variation: national policy may define the direction, but provinces, municipalities, hospitals, procurement rules, and local insurance funds shape practical access.
Side-by-side comparison
| Dimension | United States | China | Analytical implication |
|---|---|---|---|
| Primary control mechanism | Contracts, benefit design, coding, coverage, networks, and provider market power. | Administrative policy, public hospital hierarchy, reimbursement lists, procurement, and local implementation. | U.S. strategy must segment by payer and channel; China strategy must segment by policy lever, locality, and hospital role. |
| Operating variation | High variation by payer, state, employer, provider system, and plan. | High variation by city, province, hospital tier, insurance fund, and implementation rule. | Neither country can be analyzed accurately with one national average. |
| Commercial pathway | Regulatory clearance, coding, coverage, reimbursement, contracting, and institutional adoption. | Regulatory approval, reimbursement status, procurement, hospital listing, and local affordability. | Approval is only one step in both countries. |
Current evidence and sources
Drug pricing shows the sharpest contrast between U.S. plural bargaining and Chinese administrative negotiation. The United States is adding Medicare negotiation for selected high-spend drugs, but it still operates through a layered system of list prices, rebates, PBMs, commercial contracts, Medicare rules, Medicaid rebates, and patient cost sharing. China uses NRDL negotiation and volume-based procurement to trade access for lower prices across public insurance and public-hospital purchasing.
U.S. negotiation is selective
CMS publishes selected drugs and negotiated prices under the Medicare Drug Price Negotiation Program, but that mechanism applies to defined Medicare products and does not replace commercial or Medicaid pricing channels.
China uses national levers
SCIO reporting on NHSA activity says hundreds of medicines were added to the national reimbursement list over six years, showing how China uses list inclusion to reshape access and affordability.
Procurement pressure
Research on China's volume-based procurement finds that centralized purchasing can lower prices and reshape market concentration, but it also requires attention to supply reliability and quality confidence.
Selected sources
Research-based interpretation
The U.S. system hides net price through contracting and rebates; China uses more explicit state bargaining and procurement pressure. The comparison should therefore be used as a decision framework, not as a static ranking of which system is better. Each system solves some problems by creating other constraints.
Comparison caution
Comparing list prices alone or assuming negotiation works the same way. A stronger analysis names the mechanism, the decision-maker, the affected patient group, and the payment or governance pathway.
How to read the comparison
Define the unit of comparison
Compare payer to payer, hospital to hospital, regulator to regulator, or workflow to workflow, not country label to country label.
Identify the control mechanism
The United States often uses contracts, coding, coverage, networks, and market power; China often uses administrative policy, public hospitals, procurement, and local implementation.
Separate formal rule from operating reality
Both systems contain gaps between written policy and practical access, adoption, affordability, and institutional behavior.
Strategic meaning
For cross-border healthcare strategy, this comparison matters because product-market fit is institutional. A technology, drug, device, care model, or partnership that works in one country may fail in the other if it does not fit the payment, procurement, regulatory, data, and provider-behavior environment.